Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

NSCLC: Sotorasib in Practice

July 29th 2021

Experts share their real-world experiences regarding treatment with sotorasib, a new FDA-approved option for KRAS G12C-mutated non–small cell lung cancer (NSCLC).

Recent FDA-Approvals: KRAS G12C-Mutated NSCLC

July 29th 2021

An overview of new data presented at the American Society of Clinical Oncology 2021 annual meeting for KRAS G12C-mutated non–small cell lung cancer (NSCLC).

High Visceral Fat Index Associated With Worse Survival Outcomes in Early-Stage Lung Cancer

July 28th 2021

The method used to calculate how obesity is measured may impact whether it should be considered as a risk factor for non–small cell lung cancer.

Risks of Pneumonitis in Unresectable Stage III NSCLC

July 28th 2021

How to differentiate whether a patient with unresectable stage III non–small cell lung cancer develops pneumonitis from chemoradiation or durvalumab, and insight regarding techniques to help manage treatment toxicities.

Durvalumab for Unresectable Stage III NSCLC

July 28th 2021

Chaitali Nangia, MD, of the Patty and George Hoag Cancer Center, reacts to the significance of the 5-year overall survival data for the PACIFIC trial evaluating the use of durvalumab after chemoradiation as treatment for inoperable stage III non–small cell lung cancer.

Borghaei Breaks Down the Impact of Sotorasib in KRAS G12C–Mutant NSCLC and Future Research Directions

July 27th 2021

Hossein Borghaei, DO, MS, discusses the clinical implications of the FDA approval of sotorasib in patients with KRAS G12C–mutant NSCLC.

Disparities in Race and Socioeconomic Factors Linked With Outcomes in LS-SCLC

July 27th 2021

Racial minorities with limited-stage small cell lung cancer, including African American and Asian patients, were found to have more favorable survival outcomes compared with White patients, which suggests that race is associated with survival in this disease.

Analyzing the Advancing Applications for Next-Generation Sequencing in Lung Cancer

July 26th 2021

Drs Brown and Husain discuss the current and future applications of next-generation sequencing in lung cancer, the role of tissue-based testing in light of the growing role for liquid-based testing, and some of the emerging technologies that could overcome current barriers to biomarker testing.

Emerging Therapies Expand Options in Lung Cancer

July 23rd 2021

During the past 12 months, the treatment landscape for patients with non–small cell lung cancer has expanded dramatically with FDA approvals of the first drugs directed at KRAS G12C and EGFR exon 20 mutations as well as continued progress in developing new therapies for subsets of patients with other molecularly targetable alterations and with PD-L1–high disease.

Dr. Gainor on the Potential Value of Targeting TROP-2 and CEACAM5 in Lung Cancer

July 23rd 2021

Justin Gainor, MD, discusses the potential value of targeting TROP-2 and CEACAM5 in lung cancer.

Dr. Pecot on the Growth of Actionable Targets in Lung Cancer

July 22nd 2021

Chad V. Pecot, MD, discusses the growth of actionable targets in lung cancer.

ASCO 2021: New Data for NSCLC Treatment Options

July 22nd 2021

Jacob Sands, MD, reviews data regarding the investigational oral EGFR inhibitor DZD9008 that were presented at the American Society of Clinical Oncology (ASCO) 2021 annual meeting for the treatment of non–small cell lung cancer (NSCLC).

Treatment Considerations: Chemotherapy + IO in ES SCLC

July 22nd 2021

Panelists reflect on key points from recent studies in ES SCLC by discussing patients for whom immunotherapy may be appropriate, examining the role of adding CTLA4 inhibition to a PD-L1 inhibitor, and reviewing factors to consider when deciding between cisplatin or carboplatin.

NSCLC: EGFR Exon 20 Insertion Treatment Options

July 22nd 2021

Experts provide an overview of treatment options for exon 20 insertion EGFR mutations in non–small cell lung cancer (NSCLC) and trial updates presented at the American Society of Clinical Oncology 2021 annual meeting .

First-Line Therapy in ES SCLS: KEYNOTE-604

July 22nd 2021

Key opinion leader in lung cancer, Vivek Subbiah, MD, examines the phase 3 KEYNOTE-604 trial of platinum-based chemotherapy + pembrolizumab and considers whether the data support findings from other trials of chemotherapy + IO combination approaches.

Investigators Explore the Role of VS-6766 and Defactinib in KRAS-Mutant NSCLC

July 21st 2021

Patients with non-small cell lung cancer harboring KRAS mutations have been an underserved population with few treatment options, specifically those with G12V mutations.

Second-Line Therapy for Stage IV NSCLC

July 21st 2021

Second-line treatment recommendations for patients with stage IV non–small cell lung cancer who experience disease progression after immunotherapy.

Frontline Treatment of Stage IV NSCLC: What’s Next?

July 21st 2021

Future projections regarding the role of novel I-O therapies as frontline treatment for patients with metastatic non–small cell lung cancer.

Durvalumab Plus Chemo Approved in China for Frontline Extensive-Stage SCLC

July 20th 2021

The Chinese National Medical Products Administration has approved durvalumab plus standard-of-care platinum chemotherapy, in the form of etoposide plus either carboplatin or cisplatin, as a frontline treatment option for patients with extensive-stage small cell lung cancer.

ADCs for Relapsed/Refractory DLBCL: Next Steps

July 20th 2021

Tycel Jovelle Phillips, MD, reviews current therapy options for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and how he selects among these options and highlights some potential new therapies.